irinotecan/atrophy

The experimental group and the control group were administered until the disease progression assessed by the RECIST V1.1 standard (unless The investigator evaluates that the subject continues to have clinical benefits, and the subject can be allowed to continue receiving treatment), start new

Pancreatic cancer (PC) is the seventh cause from cancer and the fifth cause from cancer-related death in Europe. Nearly as many deaths occur from PC than the number of new cases diagnosed each year, reflecting the poor prognosis typically associated with this disease. PC is insidious in onset and is

1. Current Knowledge and Rationale Gastro-esophageal (GE) cancers are a highly aggressive disease and are one of the major causes of cancer-related death in the world. Despite improvements in surgical and radiation techniques and the availability of newer agents, the prognosis of recurrent GE

This study is a multicenter, open-label, randomized, phase II study comparing the efficacy and safety between fluorouracil/folinic acid plus liposomal irinotecan and fluoruracil/folinic acid monotherapy in patients with metastatic biliary tract cancer which progressed on 1st line

This study will prospectively evaluate advanced pancreatic adenocarcinoma patients. The intervention will be interleukin-1-alpha antagonist (Xilonix) in addition to standard chemotherapy. The first aim is to assess the safety and identify the maximum tolerated dose of Onivyde with

This will be an open-label, two-cohort, phase IIa study in subjects with metastatic pancreatic adenocarcinoma. The study will be comprised of 2 cohorts,. Each includes approximately 40 subjects with unresectable metastatic pancreatic adenocarcinoma. Each cohort study consists of two periods: -

PRIMARY OBJECTIVE: I. To establish the safety and tolerability of selinexor when given in combination with standard chemotherapy or immunotherapy regimens. SECONDARY OBJECTIVE: I. To determine disease control and progression free survival of selinexor administered with standard chemotherapy or

Pre-clinical and retrospective clinical data indicates hENT1 may be a predictive and prognostic biomarker for gemcitabine (Gem) efficacy. To ultimately prove its use as a biomarker, a prospective randomized study with hENT1 stratification is required. This study would provide the highest level of

OBJECTIVES: Primary - To evaluate composite efficacy and safety, in terms of objective response or tumoral stability by RECIST criteria and no deterioration in the Spitzer QoL Index score of ≥ 2 points at 4 months, in older patients with unresectable metastatic colorectal adenocarcinoma treated with